 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||||
 |
 |
 |
 |
 |
 |
|
|||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||||
 |
 |
 |
 |
 |
|
||||||||||||||||
|
|
Commercialization: Cell Targeting, Inc. Cell Targeting, Inc., a fourth company associated with The Center for Stem Cell and Regenerative Medicine, started operations in June 2005. Cell Targeting was founded by three experienced cell therapy researchers, Drs. Arnold Caplan (CSCRM, Case's Skeletal Research Center), James Dennis (CSCRM, Case Department of Orthopaedic Surgery) and David Fink. The company's products will modify the surfaces of therapeutic cells by introducing tissue-specific molecular agents capable of directing cells to target tissues. For more information on Cell Targeting, Inc. please contact David Fink at 410.258-6463. |
